22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis
This research study is looking into a new medicine called Izokibep for adults who have active psoriatic arthritis. Psoriatic arthritis can cause painful joints and skin problems. The main goal is to find out if Izokibep can help improve symptoms like joint pain and swelling more than a dummy medicine, called a placebo, after 16 weeks. We also want to understand if the medicine is safe and what side effects it might have. This study is being done in many different medical centers and involves a lot of people to get reliable results. Participants won't know if they're receiving the new medicine or the placebo, and neither will their doctors, to ensure fair testing.
At a glance
What is this study about?
When you have psoriatic arthritis, your body's immune system mistakenly attacks healthy tissues, leading to painful, swollen joints and sometimes skin rashes. Existing treatments can help manage these symptoms, but researchers are always looking for new and potentially better options. This study is testing a new medicine called Izokibep to see if it can effectively treat active psoriatic arthritis.
Imagine a large-scale test where some people receive the new medicine, Izokibep, and others receive a 'dummy' treatment, called a placebo, which looks identical but has no active ingredients. This helps researchers understand the real effects of Izokibep. Neither you nor your study doctor will know which treatment you are receiving, which helps prevent any bias in the results. The main thing they will be looking for is how many people see a significant improvement in their psoriatic arthritis symptoms after 16 weeks.
Beyond that main goal, the study will also check other important things. This includes looking at how well the medicine helps with specific types of pain like enthesitis (pain where tendons or ligaments attach to bone), how it affects skin changes, and how it improves daily activities. Safety is also a top priority, so researchers will carefully monitor for any side effects and changes in your health throughout the study. The aim is to gather enough information to determine if Izokibep could be a valuable new treatment option for people living with psoriatic arthritis.
Key takeaways
- This study evaluates a new medicine, Izokibep, for active psoriatic arthritis.
- It compares Izokibep to a placebo (dummy medicine) to understand its effectiveness and safety.
- The study focuses on improving joint pain, swelling, and other psoriatic arthritis symptoms.
- Participants will receive regular medical check-ups and monitoring.
- You have the right to withdraw from the study at any time.
Who may be eligible?
To be considered for this study, you need to be an adult, 18 years or older, and have been diagnosed with active psoriatic arthritis. 'Active' means your psoriatic arthritis is currently causing symptoms like joint pain and swelling. Both men and women are welcome to participate.
There will also be other specific medical checks to make sure the study is right for you and safe. For example, your doctors will review your medical history and current health to ensure you meet all the necessary requirements. These checks help protect your health and ensure the study results are clear and useful.
It's important to remember that these are just general guidelines. A study doctor will need to review your full medical history and current health to confirm if you are suitable for this research. They will discuss all the details with you before you make any decisions.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with psoriatic arthritis?
- Are your psoriatic arthritis symptoms currently active (e.g., painful, swollen joints)?
- Are you able to attend regular clinic visits for assessments?
What does participation involve?
Taking part in this study means you'll have regular visits to the clinic over a period of time. At these visits, you'll have various assessments, which might include having physical examinations, providing blood and urine samples, and answering questions about your symptoms and how you're feeling. You'll also receive either the study medicine (Izokibep) or a placebo, which you'll take as instructed by the study team.
Throughout the study, the research team will keep a close eye on your health and any changes, both positive and negative. They will track your symptoms, overall well-being, and any side effects. After the main treatment period, there will be follow-up appointments to ensure your health is still stable. The total duration of your involvement will be clearly explained to you if you are considered for the study.
Potential risks and benefits
Locations (6)
- —UnverifiedHungary
- —UnverifiedCzechia
- —UnverifiedPoland
- —UnverifiedSpain
- —UnverifiedGermany
- —UnverifiedBulgaria
Common questions
What is psoriatic arthritis?
It's a type of arthritis that can affect people who have psoriasis, causing joint pain, swelling, and stiffness.
What is Izokibep?
Izokibep is an investigational new medicine being tested to see if it can help improve symptoms of psoriatic arthritis.
What is a placebo?
A placebo is a 'dummy' treatment that looks like the actual medicine but contains no active ingredients. It helps researchers compare the real effects of the new medicine.
Will I know if I'm getting the real medicine or the placebo?
No, neither you nor your study doctor will know which treatment you are receiving until after the study is complete. This helps keep the study fair.
How long will the study last for me?
The exact duration for your involvement will be told to you by the study team, but the main part where they check symptoms is for 16 weeks.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.